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A bibliographical research about metoprolol succinate’s pharmacology is conducted, by which the 
mechanism of action, indications, side effects and other generalities of this drug are explained, 
giving special attention to the extended-release properties that it has been formulated with. 
Metoprolol succinate and metoprolol tartrate, two distinct salt variants of metoprolol, are 
compared. Differences in indication, posology and formulation between these two variants are 
explained.  
With help of bibliographical examination, a manufacturing process for this medicinal product is 
proposed in a large-scale setting. The different stages of industrial production of extended-release 
tablets are explained in detail.  
Also, and considering the importance of reducing the environmental waste derived from industrial 
activity, a new design for the packaging is proposed in order to make a more eco-friendly product, 
reducing waste of cardboard and plastic. 
This dissertation intends to sum up knowledge about metoprolol succinate as the first necessity 
medication for developed countries that it is. Throughout this work, a glance regarding the whole 
process of transformation of metoprolol succinate is taken, from the molecule and through its 
galenic development to the environmental impact that it has. 
_____________________________________________________________________________ 
 
Es desenvolupa una recerca bibliogràfica de la farmacologia del metoprolol succinat per tal 
d’explicar el seu mecanisme d’acció, les seves indicacions i efectes adversos, fent especial esmena 
a les propietats d’alliberació prolongada amb les que és formulat. 
Es compara el metoprolol succinat i el metoprolol tartrat, dues variants en forma de diferents sals 
del metoprolol, i s’expliquen les diferències que hi ha entre elles pel que fa a indicacions, posologia 
i formulació.  
Amb l’ajuda de la bibliografia consultada, es proposa un procés de fabricació per a aquest 
medicament a escala industrial per fer comprimits recoberts d’alliberació prolongada i s’expliquen 
les diferents etapes de producció. 
Per últim, fent evident la necessitat de disminuir l’impacte ambiental de la producció industrial, 
es proposa un nou disseny de condicionament primari i secundari per tal d’oferir un producte més 
ecosostenible, reduint el consum de cartró i plàstic.  
Vist en perspectiva, aquest treball intenta resumir el coneixement relatiu al metoprolol succinat, 
com a medicament de primera necessitat que és en països desenvolupats, a través d’una lectura 
transversal que comprèn des del procediment de transformació de la pròpia molècula activa fins 





The final monography of a degree (Treball de final de grau) is an academic work that challenges 
students to work autonomously in order to put in practise concepts, abilities and skills learnt 
through the development of the degree. 
The pharmaceutical world is competitive and demanding in the same way that the degree is.  
In spite of all work and effort graduates must put to have a successful university experience, 
pharmacy covers many interesting knowledge areas.  
In my humble opinion, one of the most fascinating topics of this degree has been learning and 
understanding the science by which a molecular compound with medicinal properties can be 
transformed into a pharmaceutical product.  
We live in a moment of history where the world is globalised; technology has allowed an 
exponential growth in medicine, making medication accessible almost all around the globe.  
Being interested in both pharmaceutical designing and technology, it is no wonder I made the 
decision of choosing pharmaceutical technology as the main area of study of my final dissertation 
project.  
 
Integrating educational scopes: 
The three major academic scopes of this essay are pharmaceutical technology, environmental 
managing and pharmacology.  
The present work is a bibliographical exercise where I intend to expand my knowledge in 
pharmaceutical technology, industrial equipment and techniques, at the same time that I study 
the environmental impact that industrial production has and research the pharmacological 









The essay has several objectives: 
- To review the pharmacological theory of beta-blockers and metoprolol in particular. 
- To analyse the pharmaceutical dosage form of metoprolol succinate and study its 
excipients. 
- To propose an industrial tablet manufacturing process for metoprolol succinate. 
- To comment the impact that pharmaceutical products have upon the environment. 
- To eco-design a new packaging for metoprolol succinate to create a more sustainable 
product. 
 
The organization of this dissertation has been planned along the first term of 2018.  
The first ideas were born during the months of January and February as the result of a couple 
brainstorms. For example, these initial ideas included the design of an eco-friendly packaging, 
which has been materialized in the present work. 
The major part of the research was made in the following weeks. It was a literature research with 
the support of books, articles, reports, web pages and other online documentation.  
The writing process began in April and was extended until the end of May, when the revision, 
correction and stylisation of the final document were done. 












Beta-adrenoceptor blocking agents are a class of drug that are widely prescribed for the treatment 
of cardiovascular disease, heart failure and hypertension. They were first identified by James W. 
Black in 1962, at the Imperial Chemical Industries in the United Kingdom(1), being propranolol the 
first beta-blocker with therapeutic use. Since then, beta-antagonists have been widely prescribed 
in cardiovascular medicine, reducing morbidity and mortality by as much as 90% in acute 
coronary syndromes.(2) 
Black was awarded the 1988 Nobel Prize in Medicine jointly to Gertrude B. Elion and George H. 
Hitchins for "their discoveries of important principles for drug treatment”.(3) 
To later understand the mechanism of action of beta-blockers, we should first review some basic 
concepts: 
 
Catecholamines are organic compounds formed by a cathecol group and a side-chain amine that 
act as neurotransmitters or hormones.  
In particular, epinephrine is an hormone released by the adrenal gland whereas norepinephrine 
is mainly released by neurons in the brain as a neurotransmitter, even though there is a small 






       
      
These two molecules play a crucial role in our body’s sympathetic nervous system, in what it is 
known as the fight or flight response. 
 
 
Figure 1: Molecular structure of 
norepinephrine (also known as 
noradrenaline) (5) 
Figure 2: Molecular structure of 






By binding to alpha and beta receptors, epinephrine and norepinephrine prepare the body to 
respond to a perceived harmful event, that can range from stressful situations to potential threats 
to survival.  
This response involves physiological changes such as acceleration of the heart and lung action, 
dilation of blood vessels, inhibition of salivation, digestion and more.  
To make it simple, this sympathetic reaction causes a higher heart rate and an increased blood 
flow (diverted from non-essential organs to the muscles and brain, supplying sugars and oxygen) 
and also speeds up the coagulation process (preventing excessive blood loss, in case of an injury).  
This last nuance will play a major role in the understanding of the treatments with beta blockers.(6) 
 
 
Adrenoreceptors are a class of G protein receptors that, when activated by norepinephrine and 
epinephrine, induce the sympathetic autonomous system and thus the fight or flight response 
previously explained. 
There are two main types of adrenoreceptors, alpha and beta, and each one of these has its own 
subtypes: α1, α2 and β1, β2 and β3. 
In one hand, alpha-1 receptors are mainly found in smooth muscles, while alpha-2 are found in 
presynaptic nerves.  
In the other hand, beta-1 are found in cardiac tissue, beta-2 in vascular and bronchial smooth 
muscle and beta-3 in fat tissue.(2) 
β2 –receptors are mostly involved in the fight or flight response in a muscular level, whereas β1 
are responsible for the increase of cardiac output. However, the heart also possesses β2 receptors, 






When norepinephrine binds to β-receptors in a 
cardiac myocyte, as shown in figure number 3, 
there is an increased amount of cAMP produced, 
consequence of the action of the adenylyl cyclase 
over ATP molecules. 
This higher concentration of cAMP will result in an 
overexpression of PK-A, thus causing a greater flow 
of Ca2+ ions into the myocyte by phosphorylating 
calcium channels. The more amount of Ca2+ that 
enters to the cell during action potential, the bigger 
will be the amount of Ca2+ released by the 
sarcoplasmic reticulum. This action results in more 
contractions, leading to a higher heart rate.(1,7) 
(Note that the arrow signalling the binding of NE 
with β1 is thicker than the one with β2).  
 
β
β-blockers, as we have seen before, act as competitive inhibitors of β-adrenergic receptors. 
Therefore, catecholamines may not properly bind to adrenoreceptors, meaning that their effect 
will be substantially reduced. 
β-antagonists can be classified in 3 generations: 
 1st Generation comprises non-selective agents like propranolol and timolol. 
 2nd Generation consists of selective β1 agents that act solely upon these receptors. In this 
group we find metoprolol and atenolol. 
 3rd Generation is made up of non-selective or β1-selective agents that have vasodilation 
properties. In this group we find nebivolol and carvedilol.  
Some of the main effects of these drugs are the reduction of heart rate (slowing down the 
sinoatrial node), the decreased formation of arrhythmias (due to a reduced contractibility) and a 
diminution of blood pressure (by dilation of cardiac artery).(4) 
 
Figure 3: Beta-adrenoceptors coupled to Gs-proteins and cAMP 
formation in the heart. cAMP modulates cardiac myocytes’ 
contractions.(7) 
Abbreviations: NE, norepinephrine; Gs, G-stimulatory protein; AC, 
adenylyl cyclase; PK-A, cAMP-dependent protein kinase; SR, 




Metoprolol succinate is a second generation beta-blocker, as seen before. It acts binding 
selectively to β1 receptors, antagonizing adrenergic effects. 
The molecular formula of metoprolol succinate is (C15H25NO3)2·C4H6O4, and its IUPAC name is  
butadenoic acid; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino9propan-2-ol.(8)  
The molecular weight of this compound is approximately of 652.826g/mol.  
It is one of the salt forms of metoprolol, alongside metoprolol tartrate. Being a salt makes this 
compound highly soluble in water. It is also considerably soluble in methanol, but it is practically 
insoluble in acetone or diethyl ether. 
It is distributed as a powder, which must be stored at room temperature.  
Accordingly to the Hazard and Precautionary Statements from the GHS, it is considered harmful 
if swallowed, damaging to organs and skin irritating, while it also hazardous to aquatic life with 













Metoprolol is a drug that can be presented both as metoprolol succinate and metoprolol tartrate. 
Even though the pharmacophore is the same, there are differences between the two API, and 
one of them is the indications they both have. [Those differences will be reviewed later in this 
document]. 
Metoprolol succinate is an EMA and FDA-approved drug for hypertension, angina and heart 
failure. At the same time, metoprolol tartrate is approved for hypertension, angina, and 
prevention of heart attacks.(9)  
In the following sections we will see in detail the different indications of metoprolol succinate. 
Heart failure  
Heart failure is a chronic condition in which the heart muscles are progressively getting weaker 
and the body’s oxygen and blood needs are not met, since not enough blood is bumped.  
The body has some compensatory mechanisms, but in the long-term they are not enough to 
solve the problem. These mechanisms include developing more muscle mass and enlarging the 
heart (letting the heart pump strongly), diverting blood away from non-essential organs to the 
heart and brain and also hastening the heartbeat.(10) 
Treatment for heart failure depends on its severity. Pharmacological treatment includes ACE-I 
(angiotensin converting enzyme inhibitors) and beta-blockers, usually in association. Exercising, 
quitting smoking and planning a healthier diet are recommended in all scenarios.(11) 
Hypertension 
Hypertension is a common diagnosed condition in which the blood pressure in the arteries is 
consistently elevated. It is a global health concern because it leads to a major risk for coronary 
disease, strokes, heart failure and other related pathologies.(12) 
Lifestyle changes are the first recommended treatment for non-severe cases. However, since 
hypertension is one of the most prevalent conditions worldwide, millions of patients use 
medication to treat it.  
Amongst the most frequently prescribed drugs for hypertension we find ACE inhibitors, calcium 





Angina is the name given to the chest pain caused when the heart muscle does not receive 
enough oxygen. The feeling of discomfort feels like a pressure or squeezing in the chest and can 
also be extended to arms, shoulders, neck or back.(14) 
Angina can be classified depending on the pattern:  
 Stable angina (also known as angina pectoris or chronic angina):  is caused when the 
heart is working more than what it usually does, for example doing some physical activity 
like exercising. Since it has a regular pattern it can be predicted and sometimes avoided. 
Resting can alleviate stable angina, and even though the most common pharmaceutical 
option is nitroglycerin, beta-blockers such as metoprolol are also considered.  
 Unstable angina: unlike stable angina, unstable angina shows itself with no apparent 
pattern and it can even occur during rest. It is considered far more dangerous, because 
it can be a sign of immediate or potential heart attack and rest or medication do not 
relieve it. In severe cases, surgical procedures like a percutaneous coronary intervention 
(PCI) or a coronary artery bypass graft surgery are performed.(15)  
 Pinzmetal’s angina (also known as variant) and microvascular angina are two types of 
angina characterized by an abnormal narrowing of the blood vessels without being led 
by a coronary disease. Nitrates and calcium-antagonists are the mainstays of these 
angina’s treatments.  
 
 
Metoprolol succinate is not suitable for everyone. It should not be prescribed if the patient is 
prone to have bradycardia or hypotension, second- or third-degree atrioventricular block, blood 
circulation problems, arrhythmias or in case of allergy to any of the components. It is not meant 
to be used in patients with unstable coronary artery disease nor in cardiogenic shock, either. 
Also, in case of asthma, emphysema or any other respiratory distress disease and in renal 
insufficiency, dosage should be individually calculated and monitored. (16–18) 
 
 
Common side effects of metoprolol succinate, that are dose-dependent, include: dizziness, 
tiredness, drowsiness, headache, diarrhoea, itching or rash and nausea.  
Unusual cases include: depression and paraesthesia. 





In the previous unit of this academic work, we reviewed the pharmacological aspects of 
metoprolol. This section will be focused on the technological aspects involving metoprolol 
succinate. 
For that, we will first take a glance on the medicinal products containing metoprolol succinate 
95mg that have been approved by the AEMPS administration.  
There are only two options available in the Spanish market:  
 BELOKEN RETARD® 95 MG EXTENDED-RELEASE TABLETS (16)  
 METOPROLOL KRKA RETARD 95MG EXTENDED-RELEASE TABLETS (generic product)(17) 
 
 
Oral administration is generally the most accepted and used route of drug delivery. A few of the 
reasons for that are that the administration is easy, it is well accepted by patients, and that its 
manufacturing process is usually cost effective.  
Amongst all the available options, tablets are one of the most common. Not only because of the 
advantages that these dosage forms have per se, but also because they are more stable 
compared to other dosage forms.(19) 
In addition, tablets can be formulated in a way that allow an extended or modified-release. This 
is probably the reason why this dosage form was chosen for metoprolol succinate.(20,21) 
Metoprolol, as we have reviewed before, can be found in a tartrate or a succinate structure.  
Both of these structures make metoprolol a salt, which means their solubility in water is very 
high.   
Instead, what sets these two salts apart is the way they are released into the bloodstream, thus 
making their clinical indications slightly different. 
Metoprolol tartrate is a drug indicated in hypertension and angina (just like the succinate variant) 
but is also a treatment in post-myocardial infarction.  
This difference is explained by the drug’s concentration levels through time. Metoprolol tartrate 
offers an immediate release of the active ingredient, which means the concentration of the drug 
in the blood will peak. Instead, metoprolol succinate will extend the release in a constant manner 






Figure 5: Graphic representation of the difference between immediate-released and extended-released drugs  
in plasma concentration through time. (23) 
 
In comparison to metoprolol tartrate, the extended-release metoprolol succinate reaches plasma 
levels of one-fourth to one-half the peak reached by conventional metoprolol and also has a lower 
peak to trough variation.(24)     
For these reasons, the extended-release formulation of metoprolol succinate makes the 





Figure 6: Visual representation of metoprolol succinate's film-coated tablet formulation.  
The active substance is protected by a polymeric membrane made of tablet-forming excipients. The tablet is coated 
with other excipients that make swallowing easier and also help in the extensive-releasing properties.(18) 
 
The generic medicinal product of metoprolol succinate commercialized in Spain is Metoprolol 
succinato retard 95mg KRKA. The aim of this section is to display information regarding the 
excipients used for its tablet manufacturing.  
All these excipients are used in different formulation applications, but we will only describe uses 











 Colloidal anhydrous silica  
Colloidal anhydrous silica (also known as colloidal silicon dioxide or Aerosil®) is a micronized silica 
of approximately 15nm particle size. It is a non-coloured, tasteless and odourless white powder 
that is often used in the formulation of tablets because it improves flow properties of other 
excipients in the form of dry powder. It can act as an adsorbent, as an anti-caking agent and as 
a tablet disintegrant.(25,26) 
 Microcrystalline cellulose 
Microcrystalline cellulose, also known as Avicel®, is a semipolymerized purified cellulose that is 
mainly applied as a diluent in oral tablet formulations, used in both direct-compression and in 
wet-granulation processes. Additionally to being used as a filler, it can also be applied as 
disintegrant and dry binder in tablet formulations. It is a tasteless, odourless, crystalline white 
powder.(25–27) 
 
                                               






Hypromellose (also known as hydroxypropylmethylcellulose or HPMC) is a white granular powder, 
which is tasteless and odourless, that is often used in oral products as a coating agent, as a tablet 
binder and as a polymer for extended-release formulations.(25,26) 
In the case we are presenting, HPMC in a compressed nucleus is applied as a tablet binder and 
a polymer.  
 Sodium lauryl sulphate 
Sodium lauryl sulphate is a pale coloured powder –it can also adopt a flake or crystalline form- 
that has a bitter taste and smooth feel. It is an anionic surfactant used as a tablet lubricant.(25,26) 
 Polysorbate 80 
Polysorbate 80 (sometimes also referred as Tween® 80) is a yellow oily liquid that is used as a 
emulsifying and wetting agent in tablets and other pharmaceutical dosage forms, like 
emulsions.(25,26,28) 
This surfactant acts improving the wettability of the interior of the tablet, which promotes its 
disintegration. 
 Glycerol 
Glycerol, also known as glycerine, it is a substance used in a wide variety of formulations. 
In tableting it is used as a humectant solvent, preservative and as a sweetener. It is a clear, 
viscous liquid. It has a sweet taste, but it does not have colour or any odour.(25,26) 
 Hydroxypropylcellulose 
Hydroxypropylcellulose is a pale yellow, tasteless and odourless powder that is used in oral 
formulations as a film-coater, as a tablet binder and as a modified-release matrix former.  
Depending on the concentration of this substance, it can be used in direct-compression tableting 
or in the production of extended-release tablets. 
It is known that the quickness of the release is inversely proportional to the viscosity of 
hydroxypropylcellulose. It is also remarkable that if an anionic surfactant (like sodium lauryl 
sulphate, whose application we have already described) is added into a formulation containing 
hydroxypropylcellulose, the viscosity of the cellulose increases, thus the release of the drug is 
extended.(25,26) 
 Ethylcellulose 
Ethylcellulose is an ethoxylated-cellulose, tasteless and colourless, that is commonly used as an 
excipient in oral formulations. Although its primarily use is being a coating product, masking an 





 Sodium stearyl fumarate 
Sodium stearyl fumarate is a commonly used tablet lubricant at 0.5-2.0% concentration 
(weight/weight, w/w). It is a fine, white powder that usually contains agglomerated particles, in 
a flat and circular-shaped form.(25,26) 
 
 
 Hypromellose  
HPMC, as presented previously, is a granular powder used as a tablet binder or as a coating 
agent.  
In the case we are presenting, HPMC is used as a binder for the core of the extended-release 
tablet of metoprolol succinate and as a coating agent in the process of film-coating the nucleus 
of the tablets.(25,26,29) 
 Titanium dioxide 
Titanium dioxide (TiO2) is a white tasteless and odourless powder used as a white pigment and 
opacifier in film-coated tablets. (25,26) 
 Talc 
Talc is a very fine crystalline powder used as a tablet lubricant and glidant. It has a white to light-
grey colour and it is odourless. It has a soft touch, being almost impalpable and unctuous.(25,26) 
 Propylene glycol 
Propylene glycol is a colourless clear, viscous liquid with a sweet, acrid taste that is commonly 




Given that the access to bibliography regarding the specific manufacturing process of metoprolol 
succinate is limited, this section of the dissertation will be an attempt to recreate the fabrication 
process based on theoretical information found in books and articles. Note that since no 
bibliography regarding formulation, proportion of excipients or batch sizes was found, no 
comments on that aspect will be done. This is an exercise that requires analysing the theory and 
synthesising the acquired knowledge, and might not represent faithfully the way this medicinal 
product is industrially manufactured. 
Once that statement is made, it is important to emphasise that the list of excipients reviewed 




In the current time in industry, big firms often possess advanced technology in their 
manufacturing process. Even though the cost of large machinery is high, the results are more 
efficient, reliable and of a great quality and improved safety.(20) The process of tableting can be 
done by three different mechanisms: direct compression, dry and wet granulation. 
Direct compression is the simplest, most straightforward way to produce tablets since it has fewer 
process stages than granulation options, leading to a faster production. The choice to use direct 
compression will be determined by a few factors. Excipients must have the exact flow and 
compression characteristics. The process of direct compression involves weighting the excipients 
and the active substance, milling and mixing them, in order to later compress them altogether.(30) 
Alternatively, on the one hand there is dry granulation, a form of oral dosage production 
wherein small particles are adhered together to form granules that will make compression 
easier, all in fewer steps than in wet granulation.(31) Those steps include: weighting, milling the 
powders, blending them, compacting the mix of powders through a roller compactor to form 
sheets of compressed material, which are then milled into granules, lubrication of granules and 
final stage compression. Compared to wet granulation, there are no humectant liquids involved 
in the procedure.(30) 
On the other hand, wet granulation involves similar steps but also includes a step in which 
humectants and wetting agents are added to a pre-mixture to increase the binding of the 
excipients that form the granules. After the liquid is added, granules are dried so their intrinsic 
humidity is removed.(20) 
 
 





As reviewed before, the generic version of metoprolol succinate approved by the AEMPS contains 
three liquid excipients (propylene glycol, glycerol and polysorbate 80), in which the first is used 
in the coating step and the last two are used in the granulation process.  
Because of that, the most suitable option for the manufacturing of tablets in this particular case 
is wet granulation. 
Needless to say, every single step of the manufacturing process has to follow GMP (Good 
Manufacturing Practices), not only because it is legally required but also because it is the best 
way to ensure pharmaceutical quality and safety.(32) 
WEIGHING 
The proposed manufacturing procedure starts with the weighing of the active substance and 
excipients. All compounds must comply the expected quality in order to guarantee the safety and 
efficacy of the potential tablets. To do so, excipients will be sent to a weighing room where trained 
operators will carefully weigh all of them with the adequate scales and later store them in tagged 
containers.(20) 
GRANULATION 
Subsequently, some excipients are used in what it is the first phase of granulation. 
 
Figure 8: Industrial manufacturing process often use lined-up sets of equipment to improve efficiency.(33)  
 
 
In order to do so, the active substance and the first excipients are placed in a container. The 
material is then charged into a high shear mixer granulator with previous sifting to uniformize 
particle size. 
In yellow, the high shear mixer 
granulator. The content can be 
transferred from the container 
through vacuum pump. 
 
In red, a high-speed security sifting. 
The powdery excipients are sieved. 
 
In green, the container where the 
active substance and excipients will 




The excipients that will be used in the first phase are: colloidal anhydrous silica, 
microcrystalline cellulose, hydroxypropylcellulose and part of hypromellose (a certain 
amount will be used in the coating process).(27) 
Once in the high shear mixer, these compounds will be vigorously mixed by an agitator (n2) and 
a chopper (n1). (See Figure 9) 
An industrial mixer might be represented by the following diagram. The powdery excipients are 
transferred through the charging canal and the liquid binders are added with a sprayer after a 
set time. Molecular nitrogen is added to facilitate the mixing procedure right before the binders 
are added. 
 
Figure 9: Shear mixer internal structure; powder gets mixed by a chopper (n1) and an agitator (n2).  
Binders are sprayed while the mixture is being conducted.(31) 
 
In our case, the liquid components are polysorbate 80 and glycerol, acting as humectants and 
wetting agents. 
After the mixture finishes, the wet granules formed are discharged with a wet sieve to 
homogenize particle size and are later sent into a dryer. 
Usually, for the drying of granules it is used a fluidized bed dryer. This is an equipment that 
reduces the moisture content from granules and powders. Hot air is introduced at high pressure 
through a perforated plate, lifting the granules and keeping them suspended in an airstream. The 






Figure 10: Fluid bed dryer. Warm airflow suspends granules and dries them by removing the moisture that they contain. 
The humidity loss of these granules is cleared by filters.  
After a set time, when granules are dried, they go through a sieve to homogenize particle size. (20) 
The dry granules go through a sieve and are transferred to a final mixer, where there will also be 
added the lubricant substances. In our case, those are sodium stearyl fumarate and sodium 
lauryl sulphate.  
 
Figure 11: Lubrication container. Non-lubricated granules and lubricating excipients are placed in a rotary container that 
will mix both of them.(33) 
 
With that, lubricants will stick to the formed granules, giving them better flowing properties and 
a better compressibility. Finally, the product obtained from the granulation will be compressed.  
The mixed wet granules are 
transferred from the high shear mixer 
to the fluid bet dryer, going through a 
second sieve. 
The heated airflow makes granules 
move and lose their moisture. The 
excess of humidity is then removed 
through bag filters and finally the 
granules get dry.  
 
Once the product is dry, it is sift for a 






Compression is the process in which the previously formed granules are pressed at high pressure 
to compact them together and create a tablet.  
The most used tablet press in industrial settings is the rotary press, while eccentric presses are 
usually used in the primary phases of pharmaceutical development. Rotary tablet press machines 
allow large productions and can have an output as high as 450,000 tablets per hour.(37) 
It is formed by an automated rotating turret that contains a double set of punches across it (the 
upper section of the turret holds the upper punches and vice versa), a set of dies for each couple 
of vertical punches, the feeder, the compression rolls and the ejection site. Additionally, these 
machines usually have control mechanisms by which parameters like weight, centrifugal velocity, 
and applicable pressure can be regulated depending on the situation. 
Precompression is the process where punches exert a first amount of pressure to remove traces 
of air that are trapped within the powder. In the main compression a higher pressure is applied 
in order to compact the granules into tablets with the desired hardness. In both of these 
situations, punches move by the compression rolls; upper punches will move down because of it 
and compression will take place. After the upper and lower punches lose contact with the 
compression rolls, the upper punches will be lifted by the upper cam and at the same time the 
lower punches will be moved by the ejection cam and tablets will be pushed out of the die cavity 
and discharged.(38) 
Usually, the number of tablets obtained per revolution coincides with the number of dies that the 
turret has.(37) It is also worth pointing out that punches are one of the most crucial and delicate 
pieces of the tablet press. They can be specifically design for every type of tablet and they 
















The last step of the manufacturing process of tablets is coating.  
Even though it is an optional step in conventional tablets, in our case proposing a manufacturing 
process for metoprolol succinate it is necessary. 
As reviewed before, four excipients of the formulation are involved in the film-coating of the 
tablets 
Hypromellose, not only used as a tablet binder but also as a coating agent, and propylene 
glycol are going to be used as the two major coating components. Both talc and titanium 
dioxide are excipients that will grant extra quality attributes. Titanium dioxide is a powder that 
gives a white pigment and opacifies tablets, while talc grants the best lubrication and gliding.  
In order to start the coating procedure, the batch of compressed tablets will be loaded into a 
drum coating system. The drum will start spinning, slowly moving tablets around. Warm air will 
flow continuously and eventually the rest of the excipients (mixture of liquid and powders) will 
be sprayed. The combination of parallel spraying and spinning results in a uniformed coating.  
Once the coating is uniform, there is a drying lapse and a posterior cooling-down of the 
machine.(20,36) Tablets will now be coated. 
 
Figure 13: Representation of the coating process. The charged drum spins moving tablets around at the same time that 







After the manufacturing of the tablets, packaging is what follows.   
Some tablets will be used as samples to analyse the lot quality; if tests are successful, the rest of 
the tablets will be stored in the designed packaging. 
The primary packaging of a medicinal product consists in the protection of the pharmaceutical 
dosage form. In our case, the primary protection is a blister, even though other options could be 
considered. The main goal of creating this primary packaging is maintaining the integrity of the 
product.  
The blistering procedure is also highly mechanized, since the portion of tablets produced in one 
lot is usually very large. The equipment used contains stationary and moving parts that are meant 
to help produce the blister sets. Through many electromechanical movements, the machine 
produces cavities on mouldable web materials, fills those cavities with the tablets and covers 
them with the adequate material.(40) 
Blisters from metoprolol succinato 95mg KRKA are made of Alu/PVC (one aluminium side and a 
polyvinyl chloride, plastic one). For this packaging, large rolls of PVC are placed in the feeding 
rollers. Those rollers will make them move and undergo through a heating box that will form 
bubble-like cavities. After that, tablets are going to be placed in the formed pockets with the help 
of automated and synchronized mechanisms.  
Right after, the blister is formed after a seal station covers the tablets in their pockets with the 
second material used. Sealing is accomplished with applied temperature, that differs depending 
on the material used. Once the blister is sealed, it is moved to the printing station, where 
important information is engraved. There is usually information about the product, the dosage 
and the manufacturer, but the expiry date and the lot identification number are always printed.  
Then, blister packs are moved into the last station, where they are trimmed into individual units 
and ejected from the machine line.(40,41)  
 
Figure 14: Schematic representation of the blistering procedure: cavity formation,  






Pharmacokinetically, metoprolol succinate’s absorption is fast and almost complete. Its plasma 
half-life ranges from 3 to 7h. However, plasma levels achieved after oral administration are 
variable interindividually. 
It is metabolized by the liver and a 5% of the dose is recovered unchanged in the urine.(24)  
This unaltered percentage of metoprolol and other metabolites are excreted through urine, thus 
making their way to the sewage.  
Just like metoprolol, there are many medicinal products that end up in the sewage. Most of them 
can be considered emerging contaminants, which can be defined as a group of compounds that 
raise toxicological concern for the environment and are not yet legislatively regulated but might 
be in a future.(42) They are candidates to undergo studies on their effect upon aquatic life forms 
and the environment.  
Pharmaceutical products are not always removable in residual water treatment plants with the 
conventional treatments.  
Alternative treatments such as advanced oxidation processes (AOPs) might work best to treat 
medicinal products.(42) 
The number of contaminants reaching wastewaters does not exclusively come from households, 
but also from hospitals, from production plants of pharmaceutical industries and from livestock 
treatment waste. 
Metoprolol is classified as “dangerous for the environment”.(43) It can be found in wastewater 
treatment plants and even in rivers(44) and they must be treated accordingly to prevent potential 
environmental damage. 
However, water pollution is not the only environmental concern to consider. Water consumption, 
plastic use and paper waste are also material goods whose usage must be reduced in any 
circumstance.  
The protection of the environment has become increasingly transcendental and pharmaceutical 
industries are facing the challenge of reducing and preventing environmental pollution without 






As an example of a plan proposed to reduce waste in a pharmaceutical perspective, I have re-
designed the secondary and primary packaging (cardboard and blister format, respectively) of 
metoprolol succinate. The model for the comparison has been, like in other sections of this 
dissertation, Metoprolol succinato retard 95mg KRKA. 
According to the World Health Organization, efforts should be made to reduce the surface and 
weight of packaging materials and to use eco-friendly, recyclable or degradable materials.(45) 
 
The current packaging looks like this:  
 
Figure 15: Picture of Metoprolol succinate KRKA. (Own content) 
 
 
   
 
 
Even though its packaging is not excessively large, there is still room for improvement.  
Length: 11.5 cm 
Width: 7 cm 
Depth: 2.5 cm 




Figure 16: Different angles of the new designed packaging for 
metoprolol succinate. Own creation using Packwire. 







The length is reduced to 8.5 cm and the width is also 8.5cm, making the packaging squared; 
also, depth is reduced to 1.5cm, since the number of blister sets is minimized from 3 (containing 
10 tablets) to 2 (containing 15 tablets). Overall, the area of the new design is 195.5 cm2. 








Length: 8.5 cm 
Width: 8.5 cm 
Depth: 1.5 cm 
Area: 195.5 cm2 
The new packaging is designed to contain only two blister sets, instead 
of three. This is why the depth of the packaging has diminished. 
x2 
Another eco-friendly feature that has been proposed is to substitute 
the blister being Alu/PVC to Alu/Alu. 
Aluminium can be more easily recycled than plastic materials, 
therefore the option of using blisters Alu/Alu has been chosen.(45) 
 
Figure 17: Representation of the 





Comparing the areas of the two designs, the new one is 23% smaller. The amount of cardboard 
used and the weight of the packaging have been considerably reduced. The area of the new 
packaging represents a 77% of the current version (23% smaller). 
 
𝑎𝑟𝑒𝑎1   108.375 𝑐𝑚
3
𝑎𝑟𝑒𝑎2   201.25 𝑐𝑚
3
× 100 = 77%  
 
No data bibliography has been found regarding how many people use KRKA’s metoprolol 
succinate.  
In spite of that, the obtained numbers will be extrapolated to understand the impact made by 
the new design’s area diminishment. 
In the event of manufacturing 100,000 units, the amount of cardboard reduced in cm2 would be: 
 
100,000 𝑛𝑒𝑤 𝑝𝑎𝑐𝑘𝑎𝑔𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠  ×  (253.5 −  195.5𝑐𝑚2) =  5,800,000 𝑐𝑚2 =   580𝑚2  
 
A hundred thousand units represent 580 m2 fewer cardboard. At first, it may not seem a huge 
difference, but if eco-design was adopted by all pharmaceutical companies the reduction of 








 Metoprolol succinate is a medicinal product with extended-release properties given by a 
special formulation, which has been thoroughly commented in the present work.  
 
 Because of the fact that this medication has a sustained release, patients only need to take 
one tablet per day, thus improving therapeutic adherence. Only two options are available in 
the Spanish market: Beloken Retard ® 95mg comprimidos de liberación prolongada and  
Metoprolol KRKA Retard 95mg comprimidos de liberación prolongada EFG. 
 
 Metoprolol succinate differs from metoprolol tartrate, another salt form of metoprolol, and 
for that reason they have different posology, physical properties and indications. The first is 
used as a treatment for pathologies such as hypertension, angina and heart failure. 
 
 For an academic purpose, scientific and commercial literature has been reviewed and all the 
acquired knowledge has resulted in a synthesised proposal of a continuous, industrial tablet 
production line, since nowadays most pharmaceutical industries use advanced technology.  
 
 Even though this dissertation is mostly a bibliographic work, a great amount of time and 
effort were destined to redesign the packaging for this medication to make it more eco-
friendly. To contribute to diminish resource waste, the new packaging has been designed to 
contain a 23% less amount of cardboard, at the same time that blisters are no longer made 
of Alu/PVC but exclusively of Alu/Alu, making it easier to recycle. 
 
 Furthermore, writing an entire essay in a non-native language has also put my language 
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